Stereotactic Body Radiotherapy for T3N0 Lung Cancer With Chest Wall Invasion

Camille Berriochoa, Gregory M.M. Videtic, Neil M. Woody, Toufik Djemil, Tingliang Zhuang, Kevin L. Stephans

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Patients with T3N0 non–small-cell lung cancer due to chest wall invasion were allowed but were not accrued to prospective studies. Thus, data regarding safety and efficacy of stereotactic body radiotherapy for such patients are limited. The present series of 13 patients with gross chest wall invasion demonstrated encouraging early clinical and radiographic efficacy with limited toxicity after stereotactic body radiotherapy in this high-risk subpopulation. Introduction The role of stereotactic body radiotherapy (SBRT) for tumors involving the chest wall (CW) remains ill-defined. The Radiation Therapy Oncology Group 0236 trial allowed inclusion of T3N0 non–small-cell lung cancer (NSCLC) < 5 cm, although ultimately none were enrolled. No published data set investigating this population is available. Materials and Methods We queried an institutional review board-approved prospective SBRT registry to identify patients with tumors involving the CW, defined as radiographic evidence of frank soft tissue invasion or bony destruction. All patients underwent SBRT to a median dose of 50 Gy in 5 fractions and were followed up for tumor control, pain response, and toxicity. Results Of 820 NSCLC patients reviewed, 13 with CW involvement were identified. Of these 13 patients, 10 had primary T3N0 NSCLC and 3 had recurrent NSCLC. Their median age was 78 years, the Karnofsky performance status was 80, the Charlson score was 3, and the tumor diameter was 4.0 cm. The 1-year local, locoregional, and distant control rates were 89%, 62%, 80%, respectively. Of 9 patients with pretreatment tumor-related CW pain, 7 (78%) reported improvement after treatment. Regarding toxicity, 2 of 13 (15%) experienced new or worsening CW pain (both grade ≤ 2); 3 cases (23%) of grade 1-2 radiation pneumonitis developed. No patient exhibited late skin changes or fibrosis. Conclusion SBRT for NSCLC involving the CW was well tolerated, with promising early rates of tumor control and no grade ≥ 3 toxicity. Tumor-related CW pain was relieved in most patients, and the treatment-related toxicity rates appeared acceptable. Further investigation in this subset of patients with NSCLC is warranted.

Original languageEnglish (US)
Pages (from-to)595-601
Number of pages7
JournalClinical lung cancer
Issue number6
StatePublished - Nov 1 2016
Externally publishedYes


  • CW invasion
  • Radiation therapy
  • SBRT
  • T3

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'Stereotactic Body Radiotherapy for T3N0 Lung Cancer With Chest Wall Invasion'. Together they form a unique fingerprint.

Cite this